Compare Lemonade Inc (LMND) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lemonade Inc vs Neurocrine Biosciences Inc — how do they compare? Lemonade Inc trades at $53 (market cap $4.09B), while Neurocrine Biosciences Inc trades at $158.84 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is far larger — about 4× Lemonade Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Lemonade Inc nearer its low. Which is the better fit depends on your goals.
| LMND | NBIX | |
|---|---|---|
Market Cap | $4.09B | $16.46B |
Sector | Financials | Health |
52-Week High | $96.57 | $185.50 |
52-Week Low | $47.38 | $123.10 |
Enterprise Value | $3.95B | $16.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lemonade (LMND) trades at $52.68, down 0.49% on the day, with technical indicators showing a bearish bias. The company reported Q2 2026 revenue growth of 79% year-over-year and has beaten EPS estimates for three consecutive quarters, yet remains unprofitable with a net income margin of -22.43% in 2025. Recent news highlights management's presentation at an Oppenheimer conference and ongoing expansion of renters insurance products.
The outlook is mixed; accelerating premium growth and a path to positive adjusted EBITDA by Q4 2026 offer upside potential, but high valuation multiples, persistent losses, and bearish technical signals present significant risks. Analyst consensus is evenly split, reflecting uncertainty around the profitability timeline.
Neurocrine Biosciences (NBIX) trades at $158.89, down 3.66% in the past 24 hours, reflecting near-term bearish technical signals. The stock shows strong fundamentals with Q2 2026 revenue growth of 39% year-over-year to $959 million and a net income margin of 20.91%. Recent news highlights include positive clinical data for INGREZZA and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.
The outlook remains positive given robust earnings beats, raised 2026 sales guidance, and a consensus price target of $208.82 implying significant upside. Risks include clinical trial setbacks, competitive pressures, and regulatory scrutiny. Analyst sentiment is strongly bullish with 86% buy ratings, supporting a growth-oriented investment case amid near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
